Nishanie Gunawardane
Psychiatry · Bloomington, INNPI 1235440082
Payments from drug & device makers
Across 140 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$276
- Sunovion Pharmaceuticals Inc.$273
- Neuronetics, Inc.$271
- Teva Pharmaceuticals USA, Inc.$241
- Alkermes, Inc.$236
- Lundbeck LLC$165
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,84999%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $276 |
| Sunovion Pharmaceuticals Inc. | 22 | $273 |
| Neuronetics, Inc. | 3 | $271 |
| Teva Pharmaceuticals USA, Inc. | 9 | $241 |
| Alkermes, Inc. | 9 | $236 |
| Lundbeck LLC | 9 | $165 |
| Neurocrine Biosciences, Inc. | 10 | $163 |
| Braeburn Inc. | 3 | $156 |
| Johnson & Johnson | 10 | $149 |
| Axsome Therapeutics, Inc. | 4 | $148 |
| Indivior Inc. | 7 | $143 |
| AbbVie(2 entities) | 8 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Avanir Pharmaceuticals, Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Orexo US, Inc. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,876 in reported general payments places this provider in the 80th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $138,542 |
| Invega SustennaPaliperidone Palmitate | 37 | $131,053 |
| AristadaAripiprazole Lauroxil | 11 | $38,015 |
| VivitrolNaltrexone Microspheres | 20 | $33,703 |
| CaplytaLumateperone Tosylate | 11 | $17,868 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 98 | $16,188 |
| TrintellixVortioxetine Hydrobromide | 27 | $15,066 |
| RexultiBrexpiprazole | 12 | $14,980 |
| Lamotrigine ErLamotrigine | 40 | $8,996 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 69 | $7,563 |
| BelsomraSuvorexant | 14 | $6,234 |
| Olanzapine | 90 | $4,861 |
| Atomoxetine Hcl | 55 | $4,688 |
| Buspirone Hcl | 118 | $4,258 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $163 | $138,54218 claims |
| Johnson & JohnsonInvega Sustenna | $149 | $131,05337 claims |
| Alkermes, Inc.Aristada, Vivitrol | $236 | $71,71831 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $105 | $19,31038 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $34 | $17,86811 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $276 | $14,98012 claims |
| Eisai Inc.Dayvigo | $17 | $3,99312 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $241 | $1,43520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Bloomington
- Richard SainiBloomington$52K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$788K
- Christopher BojrabCarmel$714K
- Joseph FanelliMunster$443K
- Anantha ShekharIndianapolis$433K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Elizabeth MartinMarion$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.